Skip to main content

Duaklir Pressair FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 6, 2020.

FDA Approved: Yes (First approved March 29, 2019)
Brand name: Duaklir Pressair
Generic name: aclidinium bromide and formoterol fumarate
Dosage form: Inhalation Powder
Company: Circassia Pharmaceuticals plc
Treatment for: COPD

Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD.

Development timeline for Duaklir Pressair

DateArticle
Apr  1, 2019Approval FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Jun  1, 2018Circassia Announces Submission of Duaklir (aclidinium and formoterol) New Drug Application

See also

Duaklir Pressair (aclidinium bromide and formoterol fumarate) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer